clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lymphadenitis D008199 8 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Mastoiditis D008417 2 associated lipids
Metaplasia D008679 7 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Myocardial Infarction D009203 21 associated lipids
Myxoma D009232 1 associated lipids
Nasal Polyps D009298 26 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nocardia Infections D009617 6 associated lipids
Endophthalmitis D009877 12 associated lipids
Psittacosis D009956 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Otitis Media D010033 12 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Pain D010146 64 associated lipids
Pancreatitis D010195 10 associated lipids
Parkinson Disease D010300 53 associated lipids
Paronychia D010304 3 associated lipids
Parotid Diseases D010305 1 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Parotitis D010309 4 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Periodontal Abscess D010508 2 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Pleural Diseases D010995 4 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Proteinuria D011507 30 associated lipids
Prurigo D011536 4 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Psoriasis D011565 47 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pyelonephritis D011704 5 associated lipids
Radiation Injuries D011832 14 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rodent Diseases D012376 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Li Y et al. Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococcus aureus infection. 2015 Drug Deliv pmid:24471983
Gunjan S et al. Clarithromycin enhances the antimalarial efficacy of mefloquine via its increased bioavailability and disrupting P. falciparum apicoplast. 2015 Life Sci. pmid:26164186
Tongtawee T et al. Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. 2015 Asian Pac. J. Cancer Prev. pmid:26163609
Fujimura S et al. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices. 2015 J. Infect. Chemother. pmid:26162777
Cavkaytar S et al. Clarithromycin regresses endometriotic implants in rat endometriosis model. 2015 J Obstet Gynaecol pmid:26156575
Bai P et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. 2015 J Dig Dis pmid:26147515
Nie W et al. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates. 2015 Biomed Res Int pmid:26146620
Kozan G et al. Effect of systemic clarithromycin and prednisolone on histamine-induced otitis media in guinea pigs. 2015 Acta Otolaryngol. pmid:26143935
Ferro BE et al. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. 2015 J. Antimicrob. Chemother. pmid:26142475
Honda M et al. Preoperative vs Postoperative Eradication of Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial. 2015 J. Am. Coll. Surg. pmid:26141464
Matsumoto T et al. Mycobacterium fortuitum thoracic empyema: A case report and review of the literature. 2015 J. Infect. Chemother. pmid:26139179
Losurdo G et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by 'geographical weighting'. 2015 Int. J. Clin. Pract. pmid:26138290
Reveiz L and Cardona AF Antibiotics for acute laryngitis in adults. 2015 Cochrane Database Syst Rev pmid:26002823
Ahmed S and Atia NN Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching. 2015 Spectrochim Acta A Mol Biomol Spectrosc pmid:25459696
Converse PJ et al. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. 2015 PLoS Negl Trop Dis pmid:26042792
Klain V and Timmerman L Comment on The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:26034875
Prapitpaiboon H et al. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. 2015 Asian Pac. J. Cancer Prev. pmid:26028098
Nayyar E and Taimur S Sporotrichoid lesions: an age-old conundrum. 2015 Am. J. Med. pmid:26021809
Harb AH et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. 2015 Aliment. Pharmacol. Ther. pmid:26011564
Rose SJ et al. Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics. 2015 PLoS ONE pmid:26010725
Srivastava AK et al. In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation. 2015 Arch. Pharm. (Weinheim) pmid:25996140
Koh WJ et al. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. 2015 Antimicrob. Agents Chemother. pmid:25987622
Tsunemine H et al. [Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)]. 2015 Gan To Kagaku Ryoho pmid:25981655
Heo J et al. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. 2015 J. Gastroenterol. Hepatol. pmid:25867608
Sugita S et al. EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. 2015 Biochem. Biophys. Res. Commun. pmid:25858318
Kesselheim AS et al. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. 2015 J Gen Intern Med pmid:25855479
Gianni C Treatment and prevention of paronychia using a new combination of topicals: report of 30 cases. 2015 G Ital Dermatol Venereol pmid:25854670
Zhang S et al. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. 2015 Cancer Lett. pmid:25853150
Zhang S and Long C Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. 2015 J. Pediatr. Hematol. Oncol. pmid:25851555
Burton AJ et al. Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. 2015 Antimicrob. Agents Chemother. pmid:25824218
Kazama I et al. Macroscopic haemoglobinuria associated with Mycoplasma pneumoniae infection successfully treated by clarithromycin. 2015 Infez Med pmid:25819056
Silva JT et al. Mycobacterium abscessus pulmonary infection complicated with vertebral osteomyelitis in a heart transplant recipient: case report and literature review. 2015 Transpl Infect Dis pmid:25816889
Sugawara M et al. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan. 2015 J. Dermatol. pmid:25809502
Andrianov M et al. A 15-year-old boy with abdominal pain, growth retardation, and anemia secondary to Helicobacter pylori-associated peptic ulcer. 2015 Pediatr Ann pmid:25806733
Zhao C et al. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012]. 2015 Zhonghua Jie He He Hu Xi Za Zhi pmid:25791651
Iino Y et al. Clinical effects of clarithromycin on persistent inflammation following Haemophilus influenzae-positive acute otitis media. 2015 Acta Otolaryngol. pmid:25649881
Streetman DS and Stout SM Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4? 2015 CMAJ pmid:25646282
Ang TL et al. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. 2015 J. Gastroenterol. Hepatol. pmid:25639278
Kimko H et al. Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen. 2015 J Clin Pharmacol pmid:25639255
Berry AC et al. Not All Helicobacter Are pylori. 2015 Clin. Gastroenterol. Hepatol. pmid:25638590
Dinca EB et al. The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:25629665
Liu Q et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection. 2015 Eur J Gastroenterol Hepatol pmid:25629566
Genc G et al. Does systemic clarithromycin therapy have an inhibitory effect on tympanosclerosis? An experimental animal study. 2015 J Laryngol Otol pmid:25619629
Winkel P et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. 2015 Int. J. Cardiol. pmid:25602299
Trespalacios AA et al. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. 2015 Diagn. Microbiol. Infect. Dis. pmid:25600075
Galvidis I et al. Group determination of 14-membered macrolide antibiotics and azithromycin using antibodies against common epitopes. 2015 Anal. Biochem. pmid:25256165
Siekmeier R et al. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. 2015 Adv. Exp. Med. Biol. pmid:25252902
Jiang F et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. 2015 Psychopharmacology (Berl.) pmid:25510856
Kim H et al. Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. 2015 Ann. Hematol. pmid:25501820
Phan TN et al. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. 2015 Int. J. Antimicrob. Agents pmid:25499186
Adebisi AO et al. Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori. 2015 J. Pharm. Pharmacol. pmid:25496042
Tsay FW et al. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. 2015 Helicobacter pmid:25495272
Mourad-Baars PE et al. Low antibiotic resistance of Helicobacter pylori in The Netherlands. 2015 Helicobacter pmid:25495199
Frija-Masson J et al. [Non-tuberculous mycobacterial infection of a totally implanted perfusion device]. 2015 Rev Mal Respir pmid:25480387
Lee H et al. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. 2015 Dig Liver Dis pmid:25467826
Dierig A et al. Antibiotic treatment of pertussis: are 7 days really sufficient? 2015 Pediatr. Infect. Dis. J. pmid:25247586
Zhang Y et al. Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. 2015 Carcinogenesis pmid:26449252
Mailleux M et al. Unusual pulmonary toxicity of ipilimumab treated by macrolides. 2015 Acta Clin Belg pmid:26790556
Jesus FP et al. In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. 2015 Antimicrob. Agents Chemother. pmid:26459895
Higuchi K et al. Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, multicenter study. 2015 Gastric Cancer pmid:25098924
Chan CC et al. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. 2015 BMC Gastroenterol pmid:26635102
Hsu PI et al. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. 2015 Medicine (Baltimore) pmid:26632893
Basyigit S et al. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study. 2015 Bosn J Basic Med Sci pmid:26614852
Shin SH et al. Helicobacter pylori Eradication Prevents Metachronous Gastric Neoplasms after Endoscopic Resection of Gastric Dysplasia. 2015 PLoS ONE pmid:26580072
Desai S et al. The Epidemiology of Invasive Haemophilus influenzae Non-Serotype B Disease in Ontario, Canada from 2004 to 2013. 2015 PLoS ONE pmid:26569613
Rose WE et al. Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination. 2015 Pharm. Res. pmid:24934663
Nishizawa T et al. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. 2015 J. Clin. Gastroenterol. pmid:24921211
Buch T and Andersen SE [Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval]. 2015 Ugeskr. Laeg. pmid:26471025
Wu IT et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. 2015 World J. Gastroenterol. pmid:26457027
Boyanova L et al. Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance. 2015 Int. J. Antimicrob. Agents pmid:26453146
Rubio M et al. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex. 2015 PLoS ONE pmid:26448181
Barni S et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. 2015 J Investig Allergol Clin Immunol pmid:25997306
Vliegenthart AD et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. 2015 Sci Rep pmid:26489516
Zhang W et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. 2015 Gut pmid:26338726
Fasciana T et al. Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily. 2015 J. Med. Microbiol. pmid:26338221
Curth HM et al. Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study. 2015 Am J Clin Dermatol pmid:26334425
Zhu YC et al. Rapid prediction of inducible clarithromycin resistance in Mycobacterium abscessus. 2015 Mol. Cell. Probes pmid:26334290
Georgopoulos SD et al. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. 2015 Expert Opin Pharmacother pmid:26330278
Koide T et al. Analysis of Distribution of Ingredients in Commercially Available Clarithromycin Tablets Using Near-Infrared Chemical Imaging with Principal Component Analysis and Partial Least Squares. 2015 Chem. Pharm. Bull. pmid:26329859
Nozawa K et al. Effect of surfactants or a water soluble polymer on the crystal transition of clarithromycin during a wet granulation process. 2015 Int J Pharm pmid:26325306
Renvoisé A et al. Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. 2015 Antimicrob. Agents Chemother. pmid:26324275
Dingemanse C et al. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. 2015 Carcinogenesis pmid:26320104
Picoli SU et al. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. 2014 May-Jun Rev. Inst. Med. Trop. Sao Paulo pmid:24878996
UÄŸurlu T et al. Optimization and evaluation of clarithromycin floating tablets using experimental mixture design. 2014 Mar-Apr Acta Pol Pharm pmid:25272652
Skvarc M et al. Multi locus sequence typing (MLST) used as a tool to confirm the ability of susceptible Helicobacter pylori strains to gain resistance to clarithromycin during eradication therapy. 2014 Jan-Feb Hepatogastroenterology pmid:24895826
Katayama M et al. Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs. 2014 J. Vet. Med. Sci. pmid:24189617
Maev IV et al. [Eradication therapy for Helicobacter pylori infection: review of world trends]. 2014 Ter. Arkh. pmid:24779078
Katagiri S et al. [Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. 2014 Nippon Naika Gakkai Zasshi pmid:24796145
Altman E et al. Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori. 2014 Can. J. Microbiol. pmid:24392924
Kim SY et al. Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease. 2014 Clin. Exp. Immunol. pmid:24354934
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Bouricha M et al. Mycobacterium marinum infection following contact with reptiles: vivarium granuloma. 2014 Int. J. Infect. Dis. pmid:24530276
Peedikayil MC et al. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. 2014 PLoS ONE pmid:24465624
Matongo F and Nwodo UU In vitro assessment of Helicobacter pylori ureases inhibition by honey fractions. 2014 Arch. Med. Res. pmid:25240315
Hsu PI et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. 2014 Antimicrob. Agents Chemother. pmid:25070099
Sugimoto M and Furuta T Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. 2014 World J. Gastroenterol. pmid:24914361
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Ikawa K et al. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. 2014 J Clin Pharm Ther pmid:24661290
Varvyanskaya A and Lopatin A Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. 2014 Int Forum Allergy Rhinol pmid:24659566
Lee SH et al. Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. 2014 J. Clin. Lab. Anal. pmid:24652818